New Delhi: The gap between the second and precaution doses of COVID-19 vaccines from the current nine to six months may be reduced. Members of the government advisory panel NTAGI on Thursday agreed on reducing the gap. A recommendation for it will be made to the Health Ministry soon, PTI reported quoting sources.
The NTAGI’s Standing Technical Sub-Committee (STSC), which met on Thursday, also reviewed the findings of a study by the Christian Medical College (CMC) in Vellore on the feasibility of allowing as a precaution dose a Covid vaccine different from the one used for primary vaccination. The panel members found a lack of uniformity in results upon mixing jabs for booster shots and stated that no recommendation for it can be made as of now. The CMC study was on Covishield and Covaxin.
Currently, all those above the age of 18 who have completed nine months after the administration of the second dose are eligible for the precaution dose.
Discussion on Monkeypox
The threat of monkeypox and the requirement for vaccination were also discussed in the meeting, the sources said. “However, the members were of the view that a strong surveillance is what is required as of now. No case of monkeypox has been detected in the country till now,” one of the sources told PTI.
Vaccines for 6-12 age group
The panel also reviewed data on Covaxin and Corbevax vaccines for the 6-12 age group. “The members opined that data of Covid burden and mortality among children is not robust enough to take any decision to begin vaccination of those below 12 years,” the source stated.
India’s drug regulator in April this year had granted emergency use authorisation for Biological E’s COVID-19 vaccine Corbevax for those aged five to 12 years and Bharat Biotech’s Covaxin for children in the age group of six to 12 years. The STSC members were learnt to have also agreed on administration of an additional third dose for renal transplant patients before the precaution dose.
